Introduction {#sec1-1}
============

Hepatitis B virus (HBV) is a serious global health concern and an important occupational risk for healthcare workers. HBV is one of the main causes of chronic and acute hepatitis, leading to a high risk of death for cirrhosis and liver cancer \[[@ref1], [@ref2]\].

The World Health Organization (WHO) estimates that, globally, 257 million people are infected by HBV or positive for hepatitis-B-surface-antigen (HBsAg). In 2015 HBV caused 887.000 deaths, mostly by complications \[[@ref2], [@ref3]\].

In Europe, a downward trend in the rate of acute cases was observed, due to the implementation of immunization programmes across several countries in this region. However, through the changes in local testing and reporting practices, the rate of newly diagnosed chronic cases is rising over time \[[@ref4]\].

In Italy, according to the National Surveillance System (SEIEVA) data, the incidence rate of hepatitis B acute cases decreased from 5.4 per 100,000 inhabitants in 1990 to 2 per 100,000 inhabitants in 2000. This decline was even more noticeable among 15-24-year-old people, whose incidence rate decreased from 17.4 per 100,000 to 2 per 100,000 in the same lapse \[[@ref5]\].

Since 1982, safe and efficacious vaccines are available \[[@ref8]\]. According to the 2017-2019 National Plan of Vaccination Prevention (PNPV), healthcare workers (HCWs) are at maximum risk to get HBV infection and an adequate immunization intervention is essential to prevent and control the transmission of HBV in order to guarantee the protection in this group of workers. Furthermore, HBV vaccination is strongly advised for students involved in healthcare setting. The recommended schedule of HBV vaccine consists of three doses administered at the third, fifth and eleventh months of life. The target for HBV vaccine is a coverage rate of at least 95% in new-borns \[[@ref9]\].

Anti-HBs antibody levels (anti-HBs) ≥ 10 mIU/mL are considered protective \[[@ref10], [@ref11]\].

Available studies in the literature suggested that immunological memory persists even if anti-HBs titer decreases under 10 mIU/mL, as confirmed by an amnnestic response after the administration of a booster dose of HBV vaccine \[[@ref3], [@ref12]\].

Monitoring anti-HBsAg antibodies titer in serum and the eventual administration of a booster dose could be necessary in individuals at risk of exposure, like HCWs \[[@ref10], [@ref17]\].

According to the Italian law on Occupational Health and Safety (Law Decree 81/2008) \[[@ref18]\] the students, the interns and the resident doctors are also included in HCWs. When exposed to biological risk, blood tests, including HBsAg assessment and anti-HBs titer \[[@ref19]\], are evaluated. Moreover, the Italian Law Decree 81/2008 requires the employers to adopt protective measures for at risk workers, including providing safe and effective vaccines \[[@ref9], [@ref18], [@ref20]\].

The recent guidelines developed by Italian region Emilia-Romagna \[[@ref20]\] emphasise the importance of hepatitis B vaccine for all HCWs considered at risk even affecting, in some specific cases, fitness to work provided by the occupational physicians (e.g., refusing vaccination, high risk tasks, exposure prone procedures).

The aim of the study was to assess the prevalence and the persistence of a positive anti-HBs titer (≥ 10 mIU/mL) in medical students and in resident doctors with an occupational risk of HBV infection, approximately 20 years after the completion of a full regular vaccination series. The immunological memory through the anamnestic response to a booster dose in subjects with an anti-HBs concentration \< 10mIU/mL was also evaluated.

Methods {#sec1-2}
=======

STUDY DESIGN {#sec2-1}
------------

A cross-sectional, observational study was conducted. Demographic, clinical and laboratory data were collected through the review of clinical records filled in during the Occupational Health Surveillance Program.

SETTING AND STUDY POPULATION {#sec2-2}
----------------------------

The study was conducted on medical students and resident doctors undergoing periodical medical examination provided for Occupational Health Surveillance Program by the University of Ferrara from January 2011 to February 2018. Program is offered free of charge to all workers, including students, who have an occupational risk for exposure to biological, chemical or physical agents \[[@ref18]\].

Data were collected from the clinical documentation drafted during the Occupational Health Surveillance examination and included: age, gender, occupational category, vaccination status concerning HBV (date of vaccination, age at vaccination, number of doses, type of vaccine if available), blood tests (date of blood test, anti-HBs concentration, markers of HBV infection). The vaccination status was verified through vaccination certificates (a document certifying the administration of vaccines by the Public Health Department) provided by the subjects at the time of the first visit.

Only students and residents who received three doses of recombinant HBV vaccine, at 0 and subsequent 1 and 6 months from the first dose were included.

All subjects who received incomplete cycles, doses at inappropriate intervals, additional doses prior to the assessment of anti-HBs titre or who provided insufficient documentation were excluded. All subjects with a positive HBsAg surface antigen were also excluded.

The enrolled students and residents were classified according to the age at vaccination in "vaccinated during infancy", if the vaccination course was administered between 0 and 3 years and "vaccinated during adolescence", if the vaccination course was administered between 10 and 16 years. Subjects vaccinated at other ages were classified as "other age" and were excluded from the study.

The received dose was classified as "pediatric" or "adult" according to the indications of the Ministry of Health: the compulsory vaccination for HBV was introduced in Italy in 1991 \[[@ref21]\]; from 1991 to 2000, 3 pediatric doses were administered to all new-borns starting from the third month of life and 3 adult doses to all 12-year-old individuals.

Since 2000, however, the pediatric dose is administered up to 16 years of age to subjects who have not been vaccinated at birth \[[@ref19]\].

According to the WHO recommendations, an anti-HBs titer equal to or greater than 10 mIU/mL was considered as protective \[[@ref22]\]. To all subjects with an anti-HBs concentration \< 10 mIU/mL a booster dose of monovalent HBV vaccine was offered, as established by Italian law \[[@ref23]\]. The anti-HBs titer was re-evaluated at least four weeks after the administration of the booster dose, considering it protective when ≥ 10 mIU/mL.

STATISTICAL ANALYSIS {#sec2-3}
--------------------

Categorical variables were analysed as frequencies and percentages and compared by the Pearson's Chi-square test. The outcome of interest was anti-HBs concentration, considered as not protective when \< 10 mIU/mL. Levels of anti-HBs concentrations have been dichotomized in "0" when \< 10 mIU/mL and "1" when ≥ 10 mIU/mL.

The anamnestic response to a booster dose among subjects vaccinated during infancy and among those vaccinated in adolescence has been evaluated with the Fisher's exact test.

To allow the calculation of the geometric mean concentrations (GMC), in the case of undetectable concentrations, an arbitrary value of 0.5 mIU/mL was assigned, while for concentrations \> 1,000 mIU/mL, an arbitrary value of 1000 was assigned.

A multivariate stepwise logistic regression was performed considering as outcome an anti-HBs concentration \< 10 mIU/mL. The logistic regression model was build testing the following variables: gender (0 = male, 1 = female), age at vaccination (0 = infancy, 1=adolescence), vaccine dose (0 = pediatric, 1 = adult), time since vaccination (0 = \< 15 years, 1 = 15-19 years, 2 = ≥ 20 years). Odds Ratios (OR) and 95% confidence intervals (95% CI) have been calculated and a p-value \< 0.05 has been considered as statistically significant. Statistical analysis was performed with IBM^®^ SPSS^®^ Statistics, version 20.

ETHICAL APPROVAL ASPECTS {#sec2-4}
------------------------

The study protocol was approved by the Local Ethics Committee. The collection of data was conducted following the principles of the Declaration of Helsinki, according to current national legislation and in compliance with the protection of personal data. As no information which may identify the subjects was collected, no informed consent was obtained.

Results {#sec1-3}
=======

The overall population was composed of 678 students and resident doctors. 57 subjects were excluded: 23 because they received a fourth dose before the study, 27 had incomplete documentations, 6 were not vaccinated either in infancy or adolescence, 1 resulted HbsAg positive. 621 individuals met the inclusion criteria. 172 (27.7%) had an anti-HBs concentration \< 10 mIU/mL and 449 (72.3%) had an anti-HBs titer ≥ 10 mIU/mL.

None of the included subjects was vaccinated with the hexavalent vaccines Hexavac or Infarix.

The univariate analysis ([Tab. I](#table001){ref-type="table"}) showed that the percentage of subjects vaccinated during infancy with a titer \< 10 mIU/mL was significantly higher than in subjects immunized during adolescence (154/361 or 42.7% vs 18/260 or 6.9%; OR = 0.1; 95% CI = 0.1-0.2; p-value \< 0.001) ([Fig. 1](#fig001){ref-type="fig"}). The percentage of subjects who received a complete vaccination course with pediatric doses and had an anti-HBs concentration \< 10 mIU/mL was significantly higher than that of the subjects vaccinated with adult doses (162/450 or 36.0% vs 10/171 or 5.8%; OR 0.1; 95% CI = 0.1-0.2; p-value \< 0.001).

The average period between the completion of the first immunization cycle and the evaluation of anti-HBs was 20.4 years (SD = 2.2) for the subjects with titer \< 10 mIU/mL and 18.3 years (SD = 3.3) for the subjects with concentration ≥ 10 mIU/mL. The mean age of immune subjects was 25.3 years (SD = 3.4) while in seronegative individuals was 22.6 years (SD = 2.4).

The logistic regression model ([Tab. II](#table002){ref-type="table"}) confirmed the statistical significance of age at vaccination (infancy versus adolescence, OR = 0.2; 95% CI = 0.1-0.8; p-value = 0.02) as independent predictive variable associated with an outcome of anti-HBs concentration \< 10 mIU/mL.

As regards to age at first immunization, the 27.4% of subjects vaccinated during infancy and 2.3% of those immunized in adolescence showed undetectable anti-HBs titers ([Tab. III](#table003){ref-type="table"}).

The GMC of anti-HBs before booster dose was higher among subjects vaccinated during adolescence (158.2 mIU/mL with 95% CI = 128.2-194.8) than in those immunized during infancy (11.1 mIU/mL with 95% CI = 8.7-14.0).

Although a booster dose was offered to all seronegative subjects, only 94 subjects had an available blood test at the moment of the study as showed in [Table IV](#table004){ref-type="table"}: 85 vaccinated during infancy (55.2%) and 9 vaccinated during adolescence.

The rate of subjects showing an anamnestic response after the booster dose was higher in individuals vaccinated during infancy (80/85 or 94.1% vs 7/9 or 77.8%). This difference was however not statistically significant (p-value = 0.13).

After receiving the booster dose, 91.9% (57 out of 62) of subjects with a previously undetectable anti-HBs concentration and 93.8% (30 out of 32) of those with a previously detectable but \< 10 mIU/mL titer, achieved an anamnestic response (p-value = n.s.). None of the subjects resulted non-responder since they all reached an anti-HBs titer ≥ 10 mIU/mL within the secondary vaccination course (at 4^th^, 5^th^ or 6^th^ dose).

The GMC of anti-HBs after booster dose resulted 241.2 mIU/mL (95% CI = 167.7-348.7) in subjects immunized during the infancy and 72.7 mIU/mL (95% CI = 21.9-278.6) in subjects vaccinated during adolescence.

Discussion {#sec1-4}
==========

Most medical students and resident doctors included in the study (72.3%) showed, at the occupational health surveillance check, a protective anti-HBs titer even 15-20 years after the first cycle of vaccination. This finding confirms the current knowledge concerning the long-term persistence of seroprotection levels in appropriately vaccinated subjects, as described in the literature \[[@ref24], [@ref25]\].

The study showed that, 15-20 years after the primary HBV vaccination course, there is a significant difference between the rate of subjects vaccinated during infancy who did not maintain an anti-HBs concentration ≥ 10 mIU/mL and that of those immunized during adolescence (42.7% and 93.1% respectively). Similarly to other studies \[[@ref3], [@ref26], [@ref27]\], the 27.4% of subjects vaccinated during infancy also had an undetectable anti-HBs concentration and a GMC before booster dose of 11.1 mIU/mL.

Factors such as age at vaccination, vaccine dosage \[[@ref1], [@ref3]\] and host genetic factors \[[@ref28]\] play a fundamental role in maintaining the anti-HBs concentration. Furthermore, the higher the antibody response after the primary vaccination cycle, the longer the persistence of an anti-HBs concentration above the 10 mIU/mL threshold \[[@ref1]\]. The results arisen in this study reinforce the importance of age at vaccination, as highlighted by the statistical significance in the multivariate analysis (OR 0.2; 95% CI = 0.1-0.8).

The immune system in childhood is characterized by an impaired T-cell function, by lower interactions between B and T cells, by a reduced assortment of immunoglobulins and by a low affinity antibody response \[[@ref29]\].

The anamnestic response to a booster dose in individuals with an anti-HBs concentration \< 10 mIU/mL was detected, particularly in subjects vaccinated during infancy: 80 subjects out of 85 (94.1%) recovered a protective titer with a GMC of 241.2 mIU/mL. The response was less pronounced in subjects with anti-HBs concentrations \< 10 mIU/mL and vaccinated during adolescence, although no statistically conclusive hypotheses can be conceived due to the small number of available blood test. Among the medical students and resident doctors who received a booster dose, no significant difference was found in the anamnestic response between those who had an undetectable anti-HBs titer and those who had a detectable but not protective anti-HBs titer. These results are consistent with previous studies and seem to confirm the hypothesis that the immunological memory is preserved even after the loss of anti-HBs antibody titer \[[@ref10], [@ref30]\]. Such evidence acquires significance in an occupationally exposed population at greater risk for HBV. As recently pointed out by the review of Zhao and Zhou \[[@ref31]\], whether booster or revaccination after a period of time following the primary vaccination is required remains a debated issue. Nonetheless a booster response could be observed in most of subjects vaccinated 30 years ago, as confirmed by breakthrough HBV infection with severe consequences in successfully vaccinated individuals is extremely rare.

The waning immunity against HBV should be particularly monitored in high-risk groups. Occupational Physicians should consider with particular attention the evaluation of the persistence of anti-HBV specific antibodies in medical students (in most cases vaccinated at birth age) and HCWs specifically at the time of the ﬁrst employment in order to identify subjects with non-protective anti-HBs titer \[[@ref32], [@ref33]\]. Occupational Physicians' contribution to reduce vaccine delays or refusals and vaccine hesitancy that are also affecting HCWs is crucial \[[@ref34]\]. A recent study of Riccò and colleagues \[[@ref35]\] draw attention to the knowledge, attitudes, beliefs and practices of Occupational Physicians towards vaccination in HCWs showing that severity perception of the disease and misconceptions about vaccines still influence the immunization coverage. As only evidence-based recommendations should guide occupational physicians' behaviour towards vaccination, specific training programs and formations courses are strongly needed.

The main limitations of this study are represented by the intrinsic characteristics of the study design and the incomplete data of a part, albeit limited, of the clinical documentation.

In particular, at the moment of the study, only a part of blood tests was available.

Some anamnestic data could play an important role on the long-term immunogenicity of the vaccine \[[@ref36]\]. The reduced number of subjects with anti-HBs concentration \< 10mIU/mL vaccinated during adolescence did not allow to detect significant differences in the booster dose response in this subgroup. Furthermore, not all subjects eligible for the administration of a booster dose accepted the recommendation.

Conclusions {#sec1-5}
===========

The results of the study, accordingly to literature, suggest that anti-HBs titers have a tendency to decrease below the threshold of 10 mIU/mL in vaccinated subjects. Immunological memory, however, seems to persist in almost all individuals even after the reduction of the anti-HBs concentrations to undetectable levels, as observed in response to a booster dose. In conclusion, assessing seroprotection within public health programmes is not considered a cost-effective practice. In order to fill this gap, the Advisory Committee on Immunization Practices (ACIP) recommends testing health care personnel for anti-HBs antibodies levels before their occupational exposure. A positive result of the test (≥ 10mUI/mL) provides no further intervention. On the other hand, one or more additional doses of HBV vaccine and retesting is recommended in non-seroprotected subjects \[[@ref37]\]. Occupational Health Surveillance Programs represent the best opportunity to perform these activities and recommendations, allowing also both to verify the anamnestic response to booster vaccination and the persistence of immunological memory. All these actions are supported from our results and contribute to the control of HBV transmission among HCWs and undergraduate healthcare students.

Figures and tables {#sec1-6}
==================

![Seroprevalence against HBV according to the age at primary vaccination course.](jpmh-2019-03-e184-g001){#fig001}

###### 

Demographic and epidemiological characteristics.

  ---------------------------------------------------------------------------------------------------------------------------------------
                                                                              Anti-HBs \< 10 mIU/mL\   Anti-HBs ≥ 10 mIU/mL\   P-value
                                                                              (N = 172)                (N = 449)               
  --------------------------------------------------------------------------- ------------------------ ----------------------- ----------
  Gender Male (n, %)Female (n, %)                                             74, 43.0%\               170, 37.9%\             n.s.\
                                                                              98, 57.0%                279, 62.1%              n.s.

  Age at HBV vaccination Infancy (0-3 years), %Adolescence (10-16 years), %   89.5\                    46.1\                   \< 0.001
                                                                              10.5                     53.9                    

  Vaccine dose Pediatric, %Adult, %                                           94.2\                    64.1\                   \< 0.001
                                                                              5.8                      35.9                    

  Time since vaccination mean ± SD (years)                                    20.4 ± 2.2               18.3 ± 3.2              \< 0.001

  Age at testing mean ± SD (years)                                            22.6 ± 2.4               25.3 ± 3.4              \< 0.001
  ---------------------------------------------------------------------------------------------------------------------------------------

###### 

Results of a logistic regression model estimating predictors of an anti-HBs titer \< 10 mIU/mL in HBV vaccinated subjects.

  ----------------------------------------------------------------------------------------------------------------------------------
  Outcome: anti-HBs titer \< 10 mIU/mL\                                 OR                                      95% CI     P-value
  N = 621                                                                                                                  
  --------------------------------------------------------------------- --------------------------------------- ---------- ---------
  Gender MaleFemale                                                     1.0\                                    0.6-1.4    0.81
                                                                        1[^a^](#tfn001){ref-type="table-fn"}               

  Age at HBV vaccination Infancy (0-3 years)Adolescence (10-16 years)   0.2\                                    0.1-0.8    0.02
                                                                        1[^a^](#tfn001){ref-type="table-fn"}               

  Vaccine dose PediatricAdult                                           0.7\                                    0.2-1.9    0.48
                                                                        1[^a^](#tfn001){ref-type="table-fn"}               

  Time since vaccination \< 15 years15-19 years≥ 20 years               1[^a^](#tfn001){ref-type="table-fn"}\   0.7-5.5\   0.12\
                                                                        1.9\                                    0.2-3.4    0.84
                                                                        0.9                                                
  ----------------------------------------------------------------------------------------------------------------------------------

CI: Confidence Interval

^a^: reference category.

###### 

Anti-HBs concentrations (mIU/mL) and Geometric Mean Concentration (GMC) before booster dose.

  ------------------------------------------------------------------------------------------------------------------
  Anti-HBs concentrations                                                    Infancy\          Adolescence\
                                                                             (0-3 years)\      (10-16 years)\
                                                                             N = 361 (%)       N = 260 (%)
  -------------------------------------------------------------------------- ----------------- ---------------------
  **Undetectable**                                                           99 (27.4)         6 (2.3)

  1 to \< 10 mIU/mL10 to \< 100 mIU/mL100 to \< 1,000 mIU/mL≥ 1,000 mIU/mL   55 (15.2)\        12 (4.6)\
                                                                             150 (41.6)\       82 (31.5)\
                                                                             55 (15.2)\        92 (35.4)\
                                                                             7 (1.9)           68 (26.2)

  **GMC before booster dose**                                                                  

  mIU/mL (95% CI)                                                            11.1 (8.7-14.0)   158.2 (128.2-194.8)
  ------------------------------------------------------------------------------------------------------------------

###### 

Anti-HBs concentrations and Geometric Mean Concentration (GMC) after booster dose.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              Infancy (0-3 years)\   Adolescence (10-16 years)\   P-value
                                                                                              after booster dose\    after booster dose\          
                                                                                              N = 85 (%)             N = 9 (%)                    
  ------------------------------------------------------------------------------------------- ---------------------- ---------------------------- ---------
  **Anti-HBs concentration before booster dose:** anti-HBs \< 10 mIU/mLanti-HBs ≥ 10 mIU/mL   5 (5.9)\               2 (22.2)\                    0.13
                                                                                              80 (94.1)              7 (77.8)                     

  **GMC after booster dose**\                                                                 241.2 (167.7-348.7)    72.7 (21.9-278.6)            
  mIU/mL (95% IC)                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------
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